Skip to main content
Top
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Antidepressant Drugs | Research article

A surrogate measure for patient reported symptom remission in administrative data

Authors: Farrokh Alemi, Mai Aljuaid, Naren Durbha, Melanie Yousefi, Hua Min, Louisa G. Sylvia, Andrew A. Nierenberg

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Background

In real-world pragmatic administrative databases, patient reported remission is often missing.

Objective

We evaluate if, in administrative data, five features of antidepressant use patterns can replace patient-reported symptom remission.

Method

We re-examined data from Sequence Treatment Alternatives to Relieve Depression (STAR*D) study. Remission was measured using 50% reduction in Hamilton index. Pattern of antidepressant use was examined through five variables: (a) number of prior ineffective antidepressants, (b) duration of taking current antidepressant, (c) receiving therapeutic dose of the medication, and (d) switching to another medication, or (e) augmenting with another antidepressant. The likelihood ratio (LR) associated with each of these predictors was assessed in 90% of data (3329 cases) and evaluated in 10% of data (350 cases) set-aside for evaluation. The accuracy of predictions was calculated using Area under the Receiver Operating Curve (AROC).

Results

Patients who took antidepressants for 14 weeks (LR = 2.007) were more likely to have symptom remission. Prior use of 3 antidepressants reduced the odds of remission (LR = 0.771). Patients who received antidepressants below therapeutic dose were 5 times less likely to experience remission (LR = 0.204). Antidepressant that were augment or switched, almost never led to remission (LR = 0.008, LR = 0.002 respectively). Patterns of antidepressant use accurately (AROC = 0.93) predicted symptom remission.

Conclusion

Within the first 100 days, antidepressants use patterns could serve as a surrogate measure for patient-reported remission of symptoms.
Literature
1.
go back to reference Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–20.CrossRef Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–20.CrossRef
2.
go back to reference Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–86.CrossRef Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342(25):1878–86.CrossRef
3.
go back to reference Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.CrossRef Laporte S, Chapelle C, Caillet P, Beyens MN, Bellet F, Delavenne X, Mismetti P, Bertoletti L. Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies. Pharmacol Res. 2017;118:19–32.CrossRef
4.
go back to reference Holvast F, van Hattem BA, Sinnige J, Schellevis F, Taxis K, Burger H, Verhaak PFM. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study. Fam Pract. 2017;34(5):539–45.CrossRef Holvast F, van Hattem BA, Sinnige J, Schellevis F, Taxis K, Burger H, Verhaak PFM. Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study. Fam Pract. 2017;34(5):539–45.CrossRef
5.
go back to reference Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder. Am J Psychiatry. 2006;163(2):217–24.CrossRef Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, Ketter TA, Miklowitz DJ, Otto MW, Gyulai L, Reilly-Harrington NA, Nierenberg AA, Sachs GS, Thase ME. Predictors of recurrence in bipolar disorder: primary outcomes from the systematic treatment enhancement program for bipolar disorder. Am J Psychiatry. 2006;163(2):217–24.CrossRef
6.
go back to reference Bauer M, Rush AJ, Ricken R, Pilhatsch M, Adli M. Algorithms for treatment of major depressive disorder: efficacy and cost-effectiveness. Pharmacopsychiatry. 2019;52(3):117–25.CrossRef Bauer M, Rush AJ, Ricken R, Pilhatsch M, Adli M. Algorithms for treatment of major depressive disorder: efficacy and cost-effectiveness. Pharmacopsychiatry. 2019;52(3):117–25.CrossRef
7.
go back to reference Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry. 2004;61(7):669–80.CrossRef Trivedi MH, Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Key T, Biggs MM, Shores-Wilson K, Witte B, Suppes T, Miller AL, Altshuler KZ, Shon SP. Clinical results for patients with major depressive disorder in the Texas medication algorithm project. Arch Gen Psychiatry. 2004;61(7):669–80.CrossRef
8.
go back to reference Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte BP, Shon SP, Rago WV, Altshuler KZ, TMAP Research Group. Texas medication algorithm project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry. 2003;64(4):357–69.CrossRef Rush AJ, Crismon ML, Kashner TM, Toprac MG, Carmody TJ, Trivedi MH, Suppes T, Miller AL, Biggs MM, Shores-Wilson K, Witte BP, Shon SP, Rago WV, Altshuler KZ, TMAP Research Group. Texas medication algorithm project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry. 2003;64(4):357–69.CrossRef
9.
go back to reference Ten Have M, et al. Duration of major and minor depressive episodes and associated risk indicators in a psychiatric epidemiological cohort study of the general population. Acta Psychiatr Scand. 2017. Ten Have M, et al. Duration of major and minor depressive episodes and associated risk indicators in a psychiatric epidemiological cohort study of the general population. Acta Psychiatr Scand. 2017.
10.
go back to reference Maund E, Stuart B, Moore M, Dowrick C, Geraghty AWA, Dawson S, Kendrick T. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52–60.CrossRef Maund E, Stuart B, Moore M, Dowrick C, Geraghty AWA, Dawson S, Kendrick T. Managing antidepressant discontinuation: a systematic review. Ann Fam Med. 2019;17(1):52–60.CrossRef
11.
go back to reference Swanson SA, Hernandez-Diaz S, Palmsten K, Mogun H, Olfson M, Huybrechts KF. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf. 2015;24(9):934–42.CrossRef Swanson SA, Hernandez-Diaz S, Palmsten K, Mogun H, Olfson M, Huybrechts KF. Methodological considerations in assessing the effectiveness of antidepressant medication continuation during pregnancy using administrative data. Pharmacoepidemiol Drug Saf. 2015;24(9):934–42.CrossRef
12.
go back to reference Umeda T, Hayashi A, Fujimoto G, Piao Y, Matsui N, Tokita S. Medication adherence/persistence and demographics of Japanese dyslipidemia patients on statin-Ezetimibe as a separate pill combination lipid-lowering therapy - an observational pharmacy claims database study. Circ J. 2019;83(8):1689–97.CrossRef Umeda T, Hayashi A, Fujimoto G, Piao Y, Matsui N, Tokita S. Medication adherence/persistence and demographics of Japanese dyslipidemia patients on statin-Ezetimibe as a separate pill combination lipid-lowering therapy - an observational pharmacy claims database study. Circ J. 2019;83(8):1689–97.CrossRef
14.
go back to reference Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin. 2008;24(10):2805–13.CrossRef Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH. Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants. Curr Med Res Opin. 2008;24(10):2805–13.CrossRef
15.
go back to reference Locklear JC, Alemayehu B, Brody RS, Chavoshi S, Tunceli O, Kern D, Earley WR. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. Clin Ther. 2013;35(12):1923–32.CrossRef Locklear JC, Alemayehu B, Brody RS, Chavoshi S, Tunceli O, Kern D, Earley WR. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. Clin Ther. 2013;35(12):1923–32.CrossRef
16.
go back to reference Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol. 2000;15(5):279–89.CrossRef Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T. The impact of antidepressant use on social functioning: reboxetine versus fluoxetine. Int Clin Psychopharmacol. 2000;15(5):279–89.CrossRef
17.
go back to reference Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57–90.PubMed Fleurence R, Williamson R, Jing Y, Kim E, Tran QV, Pikalov AS, Thase ME. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol Bull. 2009;42(3):57–90.PubMed
18.
go back to reference Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23.CrossRef Dold M, Kasper S. Evidence-based pharmacotherapy of treatment-resistant unipolar depression. Int J Psychiatry Clin Pract. 2017;21(1):13–23.CrossRef
19.
go back to reference Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64.CrossRef Connolly KR, Thase ME. If at first you don't succeed: a review of the evidence for antidepressant augmentation, combination and switching strategies. Drugs. 2011;71(1):43–64.CrossRef
20.
go back to reference Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: which symptoms of depression are the best indicators of depression severity? Compr psychiatry. 2018;87:84–8.CrossRef Zimmerman M, Balling C, Chelminski I, Dalrymple K. Understanding the severity of depression: which symptoms of depression are the best indicators of depression severity? Compr psychiatry. 2018;87:84–8.CrossRef
21.
go back to reference Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR*D investigators group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–42.CrossRef Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G, STAR*D investigators group. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119–42.CrossRef
22.
go back to reference Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.CrossRef Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163(1):28–40.CrossRef
23.
go back to reference Alemi F. Big data: statistical analysis of electronic health record. Chicago: Health Administration Press; 2020. Alemi F. Big data: statistical analysis of electronic health record. Chicago: Health Administration Press; 2020.
24.
go back to reference Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–51.CrossRef Bet PM, Hugtenburg JG, Penninx BW, Hoogendijk WJ. Side effects of antidepressants during long-term use in a naturalistic setting. Eur Neuropsychopharmacol. 2013;23(11):1443–51.CrossRef
25.
go back to reference Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther. 2012;34(1):113–23.CrossRef Anderson HD, Pace WD, Libby AM, West DR, Valuck RJ. Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study. Clin Ther. 2012;34(1):113–23.CrossRef
Metadata
Title
A surrogate measure for patient reported symptom remission in administrative data
Authors
Farrokh Alemi
Mai Aljuaid
Naren Durbha
Melanie Yousefi
Hua Min
Louisa G. Sylvia
Andrew A. Nierenberg
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-021-03133-1

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue